The 2 year survival rate of patients with breast cancer [BC] 
Introduction
Breast cancer is one of the leading causes of brain metastases. The 2 year survival rate of patients with breast cancer [BC] brain metastases is less than 2% (1).
Treatment options for patients refractory to standard surgery and radiation are limited.
These tumors are frequently resistant to conventional chemotherapeutic drugs and antibody-based therapies which poorly penetrate the blood brain barrier (2, 3) . There is an unmet need to identify novel, targeted strategies to treat this disease.
Vstat120 is a cleaved and secreted fragment of Brain Angiogenesis Inhibitor 1
[BAI1]. The loss of BAI1 expression is observed in several cancers including glioblastoma, colorectal cancer, gastric cancer, and renal cell carcinoma. (4) The reexpression of BAI1 or Vstat120 exerts potent anti-angiogenic and anti-tumor effects in animal models of glioblastoma and renal cell carcinoma (5, 6) . Surprisingly, its expression and function has not been examined in BC. Nestin is an intermediate filament whose expression is upregulated in several cancers (7) (8) (9) . Nestin is also expressed in cancer stem cells which are known to promote cancer resistance and progression (10) . Here we determined the roles of BAI1 and Nestin gene expression in breast cancer metastases and patient survival. We found lower BAI1 expression correlates with poorer patient survival, and high Nestin expression is associated with an increased probability of metastases.
34.5ENVE is an oncolytic Herpes Simplex Virus which expresses Vstat120 and its replication is driven by a cancer stem cell specific Nestin promoter (11) . 34.5ENVE has demonstrated unparalleled anti-tumor efficacy in murine models of glioblastoma (11) . Given the roles of Nestin and BAI1 in BC brain metastases, we tested the ability of 34.5ENVE to target BC cells in vitro. In these studies, 34.5ENVE killed BC cells of varying molecular subtypes, including those known to frequently metastasize to the brain. To test the therapeutic efficacy of a Vstat120 expressing oncolytic virus [OV] in vivo, we created three new, orthotropic models of BC brain metastasis in immunecompetent FVB/NJ mice. Two of these models recapitulated the biology of human BC brain metastases [BCBM] . In both of these models, we found 34.5ENVE treatment significantly improved the survival of mice with established BCBM. in morphology and growth rate. All cells were negative for mycoplasma. RAMBO and 34.5ENVE viruses were prepared and titered as previously described (11) .
Materials and Methods

Cell
Cell Viability Assays. Cells were plated in 96 well plates and infected simultaneously with 2% FBS in DMEM containing 34.5ENVE at the indicated Multiplicity of Infection [MOI] . Viability was assessed as described previously using a standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (14) .
Virus replication assay. 500,000 cells plated in 6 well plates were infected with 34.5 ENVE at an MOI of 0.005. 3 days later cells and supernatants were harvested and the viral titers were determined via a standard plaque forming unit assay. Intracranial surgeries were performed as previously described with stereotactic implantation of 100,000 DB-7, Met-1, or Mvt1 cells (11) . Tumors were treated with HBSS or 34.5ENVE virus at the location of tumor implantation. Animals were euthanized when they showed signs of morbidity. 
Immunohistochemistry
See Supplemental Materials and Methods
Results
BAI1 expression in reduced in
Nestin expression is up-regulated in breast cancer and is associated with metastases
Nestin is up-regulated in several metastatic cancers, and its high expression correlates with reduced BC patient survival (7) (8) (9) . Nestin is also expressed in cancer stem cells known to promote cancer resistance and progression (10) . Analysis of a cohort of 166 patients stratified by median Nestin expression revealed a significant association between Nestin expression and incidence of brain and lung metastases Oncolytic virus is cytotoxic in multiple human BC subtypes 34.5ENVE expresses Vstat120 and its replication is driven by a Nestin promoter, thus we hypothesized 34.5ENVE might be therapeutically relevant for BC brain metastases.
To test this hypothesis, we tested infection, replication, and cytotoxicity of 34.5ENVE in a variety of human BC cell subtypes [ Table 1 ]. Over the course of 3 days, 34.5ENVE infected and replicated in human BC cells as determined by increasing virus encoded GFP expression [ Figure 3A ]. In vitro cytotoxicity of human BC cells to 34.5ENVE infection was dose dependent and increased with time [ Figure 3B -C]. Four days after infection at an MOI of 0.05, we observed 83.4%, 75.7%, 80.6%, and 90.1% cell death in MDA-MB-231, SKBR3, MCF7, and MDA-MB-468 cells, respectively. Most BC treatments are targeted to particular subtypes, but 34.5ENVE killed BC cells across multiple subtypes. Importantly, we observed significant killing in the Her2+ and TNBC subtypes. TNBCs are notoriously resistant to conventional therapies, and Her2+ targeted antibody treatments poorly penetrate the blood-brain-barrier. As a result, 25-55% of these BC patients will develop brain metastases. (18) These results highlight the therapeutic potential of 34.5ENVE to treat BC brain metastases.
HSV-1 replication and cytotoxicity is enhanced by the viral neurovirulence gene ICP34.5 (11) . To improve the safety and targeting of the 34.5ENVE virus, the expression of ICP34.5 is driven by a Nestin promoter. Nestin expression was increased in all 50 of the BC cell lines examined suggesting it is a relevant therapeutic target for BC [ Figure 2C ]. In order to determine the efficacy of Nestin driven ICP34.5 on tumor cell killing, we compared the cytotoxicity of 34.5ENVE with a similar virus lacking Nestin driven ICP34.5 expression [RAMBO] (11, 19 
leptomingeal metastases and did not resemble the parenchymal brain metastases commonly observed in patients (22) . Histological comparisons of patient BC brain metastases with all three murine tumors indicated DB-7 and Met-1 derived tumors most closely recapitulated the human CNS metastases and so these BCBM models were selected for further analysis [ Figure 4A ] (23).
34.5ENVE is cytotoxic to murine breast cancer cells in vitro
Human tropic viruses often replicate poorly in murine cells, so there are very few immune competent models of cancer to study OVs derived from HSV-1. To determine if we could evaluate the therapeutic effects of 34.5ENVE in this murine BCBM model, we examined the ability of the virus to infect and replicate in the DB-7 and Met-1 tumor derived cell lines. For these assays human glioma cells were used as a positive control.
We observed an increase in virus encoded GFP expression over 48 hours following infection at a low MOI consistent with virus replication and spread in these cells 
34.5ENVE treatment extends survival in vivo
We utilized MRI to non-invasively evaluate the antitumor response of 34. F12A  59PT  CWN  52PE  CC70  C812  B231  B468  LY2  C1954  B453  B157  B361  BT20  C1500  C1007  MCF7  R751  49PT  BT483  90PT  B134  0MPE  BT549  B436  B415  U565  85PE  C1937  C1187  R75B  C2185  T47D  BT474  C3153  44PE  R7530  AMA1  C1569  C1428  M1315  B435  CC38  B175  C1143  KBR3  C202  BL100  S578T  C2157 BAI1 Expres 0. 5   MC  MC  SUM15  SUM225C  SUM5  HC  UACC  MDAM  MDAM  HCC  MDAM  MDAM  MDAM  HCC  HCC  M  Z  SUM14  B  SUM19  MDAM  600  B  MDAM  MDAM  A  SUM18  HCC  HCC  ZR  HCC  T  B  HCC  SUM4  ZR  CA  HCC  HCC  SUM  MDAM  HC  MDAM  HCC  SK  HCC  HB  HS 
